Compare Kyndryl Holdings Inc (KD) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Moderna, Inc. — how do they compare? Kyndryl Holdings Inc trades at $13.02 (market cap $2.91B), while Moderna, Inc. trades at $63.54 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 8.3× Kyndryl Holdings Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | MRNA | |
|---|---|---|
Market Cap | $2.91B | $24.18B |
Sector | Technology | Health |
52-Week High | $33.14 | $81.80 |
52-Week Low | $10.59 | $22.36 |
Enterprise Value | $5.74B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $13.025, down 4.44% on the day, with a neutral technical signal. The company reported a net loss in Q1 2027, missing revenue estimates, but maintains a strong cash flow position with $942M from operations in 2025. Recent news highlights strategic acquisitions and AI service expansions, while an ongoing legal investigation introduces uncertainty. The stock's valuation shows a high P/E of 36.11 but attractive EV/EBITDA of 4.04, with analyst consensus leaning hold.
The outlook is mixed: positive cash flow and strategic moves in AI modernization offer growth potential, but recent earnings misses and legal scrutiny pose risks. Investors should weigh the company's turnaround progress against execution challenges and market sentiment.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
